{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:29:19Z","timestamp":1740104959516,"version":"3.37.3"},"reference-count":17,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:00:00Z","timestamp":1531180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Existing knowledge of medicines that increase the risk of an adverse event may be corroborated and augmented by population studies specifically assessing the risk associated with the concurrent use of these medicines and use by patients with existing comorbidity. An American Heart Association review recently identified a variety of medicines that may cause or exacerbate heart failure (HF), many with evidence from limited evaluation of population data. We assessed the risk of first\u2010time HF associated with the use of 50 of these medicines by New Zealand's primary care population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Case\u2010control study utilising national pharmaceutical use and hospital admissions data 2007\u20102015; 22,989 patients with first\u2010time HF 2008\u20102015 were matched with 114\u00a0498 control patients. The primary outcome was first\u2010time HF and its association with medicine exposure in the prior 90\u00a0days, estimated using conditional logistic regression. We also assessed the risk associated with new use of medicines in the prior month, concurrent use, and in patients with existing comorbidity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eleven medicines were significantly associated with HF with several other infrequently used medicines providing signals of increased risk. A high risk was associated with the use of salbutamol (adjusted odds ratio 2.63; 95% CI, 2.48\u20102.78), clozapine (2.70; 2.46\u20104.98), diltiazem (1.52; 1.44\u20101.60), indomethacin (2.51; 1.54\u20104.10), pioglitazone (1.50; 1.16\u20101.95), and antifungal medicines. New use of medicines and use of medicine combinations increased this risk in many cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our study provides further evidence to inform cautious use of these medicines in patients with HF or at risk of developing HF.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4586","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T06:31:39Z","timestamp":1531290699000},"page":"1019-1028","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding medicines with a propensity to increase the risk of heart failure: Combining existing knowledge with targeted population assessment"],"prefix":"10.1002","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0967-9860","authenticated-orcid":false,"given":"Andrew M.","family":"Tomlin","sequence":"first","affiliation":[{"name":"Best Practice Advocacy Centre  Dunedin New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Woods","sequence":"additional","affiliation":[{"name":"Best Practice Advocacy Centre  Dunedin New Zealand"},{"name":"Dunedin School of Pharmacy University of Otago  Dunedin New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hywel S.","family":"Lloyd","sequence":"additional","affiliation":[{"name":"Best Practice Advocacy Centre  Dunedin New Zealand"},{"name":"Department of General Practice and Rural Health, Dunedin School of Medicine University of Otago  Dunedin New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph A.H.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Green Lane Cardiovascular Service  Auckland New Zealand"},{"name":"Department of Medicine, School of Medicine University of Auckland  Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray W.","family":"Tilyard","sequence":"additional","affiliation":[{"name":"Best Practice Advocacy Centre  Dunedin New Zealand"},{"name":"Department of General Practice and Rural Health, Dunedin School of Medicine University of Otago  Dunedin New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,7,10]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000426"},{"issue":"2","key":"e_1_2_11_3_1","first-page":"79","article-title":"What the general practitioner needs to know about their chronic heart failure patient","volume":"2","author":"Rutten FH","year":"2016","journal-title":"Card Fail Rev"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S130832"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2016.01.002"},{"volume-title":"Oslo","year":"2012","author":"WHO Collaborating Centre for Drug Statistics Methodology","key":"e_1_2_11_6_1"},{"key":"e_1_2_11_7_1","unstructured":"Information Services Division NHS Scotland.Measuring long\u2010term conditions in Scotland. ISD Scotland.2008.https:\/\/www.isdscotland.org\/Health\u2010Topics\/Hospital\u2010Care\/Diagnoses\/2008_08_14_LTC_full_report.pdf Accessed 4 Apr 2017."},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0579-1"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4857"},{"volume-title":"University of Delaware: Sparky House Publishing","year":"2009","author":"McDonald JH","key":"e_1_2_11_10_1"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30069-1"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.136077"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.08.001"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02245-2016"},{"key":"e_1_2_11_15_1","article-title":"Risk of cardiovascular and cerebrovascular events in COPD patients treated with long\u2010acting \u03b22\u2010agonist combined with a long\u2010acting muscarinic or inhaled corticosteroid","author":"Samp JC","year":"2017","journal-title":"Ann Pharmacother"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.11.032"},{"key":"e_1_2_11_17_1","unstructured":"New Zealand Casemix Project Group.The New Zealand casemix sytem: an overview. December 2015 v1.2.https:\/\/www.health.govt.nz\/publication\/new\u2010zealand\u2010casemix\u2010system\u2010overview\u20100Accessed 7 July 2017."},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3197"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4586","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4586","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T15:57:32Z","timestamp":1694275052000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,10]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1002\/pds.4586"],"URL":"https:\/\/doi.org\/10.1002\/pds.4586","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2018,7,10]]},"assertion":[{"value":"2018-03-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}